ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law
PRNewswire (Fri, 21-Aug 4:38 AM ET)
PRNewswire (Fri, 21-Aug 4:38 AM ET)
ADMA Biologics Leans on ASCENIV in Earnings Call
TipRanks (Thu, 20-Aug 8:24 PM ET)
Newsfile (Tue, 18-Aug 9:18 AM ET)
PRNewswire (Mon, 17-Aug 12:10 PM ET)
Newsfile (Tue, 11-Aug 10:00 AM ET)
PRNewswire (Mon, 10-Aug 3:24 PM ET)
Business Wire (Mon, 10-Aug 8:50 AM ET)
PRNewswire (Mon, 10-Aug 8:31 AM ET)
PRNewswire (Sun, 9-Aug 3:00 PM ET)
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
Adma Biologics trades on the NASDAQ stock market under the symbol ADMA.
As of August 21, 2026, ADMA stock price declined to $9.69 with 719,206 million shares trading.
ADMA has a beta of 1.78, meaning it tends to be more sensitive to market movements. ADMA has a correlation of 0.12 to the broad based SPY ETF.
ADMA has a market cap of $2.17 billion. This is considered a Mid Cap stock.
Last quarter Adma Biologics reported $124 million in Revenue and $.16 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$.01.
In the last 3 years, ADMA traded as high as $25.67 and as low as $3.06.
The top ETF exchange traded funds that ADMA belongs to (by Net Assets): IJR, FBT, XBI, VTI, IWM.
ADMA has underperformed the market in the last year with a price return of -44.0% while the SPY ETF gained +21.1%. However, in the short term, ADMA had mixed performance relative to the market. It has outperformed in the last 3 months, returning +13.2% vs +3.5% return in SPY. But in the last 2 weeks, ADMA shares have been beat by the market, returning -3.7% compared to an SPY return of -0.4%.
ADMA support price is $9.54 and resistance is $9.98 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADMA shares will trade within this expected range on the day.